93.20
Schlusskurs vom Vortag:
$91.21
Offen:
$90.87
24-Stunden-Volumen:
871.22K
Relative Volume:
0.40
Marktkapitalisierung:
$18.65B
Einnahmen:
$7.68B
Nettoeinkommen (Verlust:
$903.80M
KGV:
20.94
EPS:
4.45
Netto-Cashflow:
$1.14B
1W Leistung:
+0.91%
1M Leistung:
+1.10%
6M Leistung:
-11.78%
1J Leistung:
-12.06%
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Firmenname
Zimmer Biomet Holdings Inc
Sektor
Branche
Telefon
(574) 267-6131
Adresse
345 EAST MAIN STREET, WARSAW, IN
Vergleichen Sie ZBH mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ZBH
Zimmer Biomet Holdings Inc
|
93.24 | 18.65B | 7.68B | 903.80M | 1.14B | 4.45 |
![]()
ABT
Abbott Laboratories
|
135.30 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
105.05 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
396.39 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
87.81 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
77.01 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
2024-09-10 | Eingeleitet | Wolfe Research | Peer Perform |
2024-07-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
2024-05-30 | Eingeleitet | Goldman | Neutral |
2024-05-21 | Hochstufung | Argus | Hold → Buy |
2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
2023-10-20 | Eingeleitet | ROTH MKM | Neutral |
2023-08-28 | Hochstufung | BTIG Research | Neutral → Buy |
2023-05-03 | Hochstufung | BofA Securities | Underperform → Neutral |
2023-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
2023-03-31 | Hochstufung | Jefferies | Underperform → Hold |
2023-03-29 | Eingeleitet | UBS | Sell |
2023-03-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
2023-01-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2023-01-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2023-01-03 | Herabstufung | Evercore ISI | Outperform → In-line |
2022-11-23 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
2022-10-18 | Eingeleitet | Barclays | Underweight |
2022-10-12 | Eingeleitet | Jefferies | Underperform |
2022-05-27 | Herabstufung | Needham | Buy → Hold |
2022-04-13 | Herabstufung | Truist | Buy → Hold |
2022-04-01 | Herabstufung | Citigroup | Buy → Neutral |
2022-03-02 | Fortgesetzt | BofA Securities | Underperform |
2022-03-02 | Herabstufung | Loop Capital | Buy → Hold |
2022-02-08 | Herabstufung | Canaccord Genuity | Buy → Hold |
2022-02-08 | Bestätigt | Citigroup | Buy |
2022-02-08 | Bestätigt | Deutsche Bank | Hold |
2022-02-08 | Bestätigt | JMP Securities | Mkt Outperform |
2022-02-08 | Bestätigt | JP Morgan | Neutral |
2022-02-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
2022-02-08 | Bestätigt | Stifel | Buy |
2022-02-08 | Bestätigt | Truist | Buy |
2022-02-08 | Bestätigt | UBS | Neutral |
2022-02-08 | Bestätigt | Wells Fargo | Underweight |
2022-02-02 | Herabstufung | UBS | Buy → Neutral |
2022-01-19 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
2022-01-10 | Herabstufung | Mizuho | Buy → Neutral |
2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2022-01-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
2021-12-10 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2021-12-09 | Herabstufung | Needham | Strong Buy → Buy |
2021-12-07 | Eingeleitet | Loop Capital | Buy |
2021-11-23 | Herabstufung | Argus | Buy → Hold |
2021-09-14 | Fortgesetzt | Raymond James | Mkt Perform |
2021-05-25 | Eingeleitet | Barclays | Overweight |
2021-04-09 | Hochstufung | Northland Capital | Market Perform → Outperform |
2021-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
2020-12-18 | Bestätigt | Needham | Strong Buy |
2020-10-20 | Eingeleitet | Northland Capital | Market Perform |
2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
2020-08-05 | Bestätigt | Needham | Strong Buy |
2020-04-28 | Herabstufung | Guggenheim | Buy → Neutral |
2020-04-09 | Herabstufung | Evercore ISI | Outperform → In-line |
2020-04-07 | Bestätigt | Needham | Strong Buy |
2020-03-05 | Eingeleitet | Citigroup | Buy |
2020-02-13 | Eingeleitet | Goldman | Buy |
2020-01-08 | Eingeleitet | SunTrust | Buy |
2020-01-07 | Hochstufung | Piper Jaffray | Neutral → Overweight |
2020-01-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
2019-12-04 | Hochstufung | Raymond James | Outperform → Strong Buy |
2019-10-07 | Hochstufung | BTIG Research | Neutral → Buy |
2019-09-18 | Hochstufung | Canaccord Genuity | Hold → Buy |
2019-08-12 | Hochstufung | Argus | Hold → Buy |
2019-07-30 | Hochstufung | Barclays | Underweight → Equal Weight |
2019-07-29 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2019-06-11 | Hochstufung | Bernstein | Underperform → Mkt Perform |
2019-04-24 | Hochstufung | Needham | Buy → Strong Buy |
Alle ansehen
Zimmer Biomet Holdings Inc Aktie (ZBH) Neueste Nachrichten
Insider Sell: Sang Yi Sells 800 Shares of Zimmer Biomet Holdings Inc (ZBH) - GuruFocus
Is Zimmer Biomet Stock Underperforming the Nasdaq? - inkl
Dental Prosthetics Market Report 2025: Global Analysis, Size, Share, Trends, and Forecast to 2032 - GlobeNewswire Inc.
Is Zimmer Biomet Stock Underperforming The Nasdaq? - Barchart.com
Zimmer Biomet Holdings (NYSE:ZBH) Is Paying Out A Dividend Of $0.24 - simplywall.st
Insider Sell: Sang Yi Sells 1,000 Shares of Zimmer Biomet Holdings Inc (ZBH) - GuruFocus
Oppenheimer Hosts Meeting for Zimmer Biomet Holdings (ZBH) on Ju - GuruFocus
Oppenheimer Hosts Meeting for Zimmer Biomet Holdings (ZBH) on June 16 | ZBH Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH) and Eli Lilly & Co (LLY) - The Globe and Mail
Treace Medical Concepts files patent infringement suit against Zimmer Biomet - Med-Tech Insights
Transcript : Zimmer Biomet Holdings, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - marketscreener.com
Zimmer Biomet at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Canada
Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis: A Look at Growth Potential with a 17% Upside - DirectorsTalk Interviews
Zimmer Biomet sued for violating Treace Medical patents related to bunion treatment - MSN
Treace Medical sues Zimmer Biomet over patent infringement By Investing.com - Investing.com South Africa
Highridge sells bone healing business to Avista - BioWorld MedTech
Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology - Ortho Spine News
Treace Medical Concepts (TMCI) Sues Zimmer Biomet Over Patent Infringements - GuruFocus
Zimmer Biomet Facing Patent Infringement Lawsuit From Treace Medical - marketscreener.com
Treace Medical sues Zimmer Biomet over patent infringement - Investing.com Australia
Zimmer Biomet faces patent suit from Treace Medical (TMCI) - Seeking Alpha
Treace Medical files patent infringement suit against Zimmer Biomet - TipRanks
Treace Medical Concepts Files Patent Infringement Suit Against Zimmer Biomet - marketscreener.com
Medical Tech Leader Treace Takes Legal Action to Protect Revolutionary Bunion Surgery Patents - Stock Titan
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Zimmer Biomet Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 31, 2017ZBH - ACCESS Newswire
zimmer biomet shareholders approve stock incentive plan amendments By Investing.com - Investing.com South Africa
Rep. Robert Bresnahan, Jr. Sells Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares - Defense World
zimmer biomet shareholders approve stock incentive plan amendments - Investing.com
Zimmer Biomet Approves Amendments at Annual Meeting - TipRanks
Zimmer Biomet Holdings (NYSE:ZBH) Has Affirmed Its Dividend Of $0.24 - Yahoo Finance
Zimmer Biomet Holdings' (NYSE:ZBH) Dividend Will Be $0.24 - simplywall.st
Zimmer Biomet sets quarterly dividend at $0.24 per share By Investing.com - Investing.com South Africa
Zimmer Biomet Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Knee Replacement Market Detailed in New Research ReportZimmer Biomet, Stryker - openPR.com
Zimmer Biomet Keeps Quarterly Dividend at $0.24 a Share, Payable Around July 31 to Shareholders of Record on June 26 - marketscreener.com
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025 - GuruFocus
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025 | ZBH Stock News - GuruFocus
Zimmer Biomet sets quarterly dividend at $0.24 per share - Investing.com
Zacks Research Forecasts Weaker Earnings for Zimmer Biomet - Defense World
Zimmer Biomet Chairman, President and CEO Ivan Tornos Joins OREF Board of Trustees - Yahoo Finance
A Look Back at Surgical Equipment & ConsumablesDiversified Stocks’ Q1 Earnings: Zimmer Biomet (NYSE:ZBH) Vs The Rest Of The Pack - Yahoo Finance
Zacks Research Forecasts Reduced Earnings for Zimmer Biomet - Defense World
Zimmer Biomet names Kevin Thornal as group president, global biz - Medical Buyer
Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas - The Malaysian Reserve
Zimmer Biomet Holdings (ZBH) Appoints Kevin Thornal as Group Pre - GuruFocus
Orthopedic Oncology Market is Booming WorldwideStryker, Zimmer Biomet - openPR.com
Zimmer hires former Nevro CEO Kevin Thornal - Yahoo Finance
Zimmer Biomet Holdings (ZBH) Appoints Kevin Thornal as Group President - GuruFocus
Zimmer Biomet names new Group President for Americas By Investing.com - Investing.com South Africa
Former Nevro CEO joins Zimmer Biomet as group president - MassDevice
Hip Replacement Market is Booming WorldwideZimmer Biomet, Stryker - openPR.com
Finanzdaten der Zimmer Biomet Holdings Inc-Aktie (ZBH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zimmer Biomet Holdings Inc-Aktie (ZBH) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Yi Sang | Group President, Asia Pacific |
Jun 11 '25 |
Sale |
95.00 |
1,000 |
95,000 |
20,424 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):